Fibrolamellar hepatocellular carcinoma in the USA, 2000–2010: A detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database-Reference-Cited by-同舟云学术

Fibrolamellar hepatocellular carcinoma in the USA, 2000–2010: A detailed report on frequency, treatment and outcome based on the Surveillance, Epidemiology, and End Results database

Published:2013-10 Issue:5 Volume:1 Page:351-357
ISSN:2050-6406
Container-title:United European Gastroenterology Journal
language:en
Short-container-title:United European Gastroenterol. j.

Author:

Eggert Tobias¹²,McGlynn Katherine A³,Duffy Austin¹,Manns Michael P²,Greten Tim F¹,Altekruse Sean F⁴

Affiliation:

1. Gastrointestinal Malignancy SectionMedical Oncology BranchNational Cancer InstituteBethesdaUSA

2. Department of GastroenterologyHepatology and EndocrinologySchool of MedicineHannoverGermany

3. Division of Cancer Epidemiology and GeneticsNational Cancer InstituteRockvilleUSA

4. Division of Cancer Control & Population SciencesNational Cancer InstituteRockvilleUSA

Publisher

Wiley

Subject

Gastroenterology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1177/2050640613501507

Reference19 articles.

1. International Agency for Research on Cancer. About CANCERMondial Available at:www‐dep.iarc.fr(accessed 6 May 2013).

2. Global Cancer Statistics, 2002

3. Primary Cancer of the Liver

4. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study

Cited by 106 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Incidence and survival of pediatric and adult hepatocellular carcinoma, United States, 2001–2020;Cancer Epidemiology;2024-10

2. Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma;Liver Cancer;2024-08-08

3. Long-term survival and remarkably durable treatment response in a case of inoperable fibrolamellar carcinoma of the liver — a comprehensive analysis of an 8-year chemotherapeutic journey;Oncology in Clinical Practice;2024-05-24

4. Multimodal imaging findings of primary liver clear cell carcinoma: a case presentation;Frontiers in Medicine;2024-05-16

5. FusionVAC22_01: a phase I clinical trial evaluating a DNAJB1-PRKACA fusion transcript-based peptide vaccine combined with immune checkpoint inhibition for fibrolamellar hepatocellular carcinoma and other tumor entities carrying the oncogenic driver fusion;Frontiers in Oncology;2024-03-28